
Dosing Milestone in Phase ½ Sarcoma Trial: Salarius Pharmaceuticals, Inc. (SLRX) Bullish After Hours
Salarius Pharmaceuticals, Inc. (SLRX) stock rebounded in the after-hours on the news of dosing milestone achievement in its ongoing trial. On December 29, the company